KR20250027597A - 사이토카인 융합 단백질과 cd8 항원 결합 분자의 조합 - Google Patents
사이토카인 융합 단백질과 cd8 항원 결합 분자의 조합 Download PDFInfo
- Publication number
- KR20250027597A KR20250027597A KR1020247039383A KR20247039383A KR20250027597A KR 20250027597 A KR20250027597 A KR 20250027597A KR 1020247039383 A KR1020247039383 A KR 1020247039383A KR 20247039383 A KR20247039383 A KR 20247039383A KR 20250027597 A KR20250027597 A KR 20250027597A
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- amino acid
- acid sequence
- cdr
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263335697P | 2022-04-27 | 2022-04-27 | |
| US63/335,697 | 2022-04-27 | ||
| PCT/US2023/019989 WO2023212056A2 (en) | 2022-04-27 | 2023-04-26 | Combination of cytokine fusion proteins with cd8 antigen binding molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250027597A true KR20250027597A (ko) | 2025-02-26 |
Family
ID=88519563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247039383A Pending KR20250027597A (ko) | 2022-04-27 | 2023-04-26 | 사이토카인 융합 단백질과 cd8 항원 결합 분자의 조합 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250339519A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4514397A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025515470A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250027597A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119546343A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023259161A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3250301A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202400664A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023212056A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230112632A (ko) | 2020-10-23 | 2023-07-27 | 애셔 바이오테라퓨틱스, 인크. | 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합 |
| WO2026162740A1 (en) * | 2025-01-31 | 2026-08-06 | Astrazeneca Ab | Cd8-binding cytokine engager combination therapies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200306301A1 (en) * | 2017-07-03 | 2020-10-01 | Torque Therapeutics, Inc. | Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof |
| JP2020533971A (ja) * | 2017-08-28 | 2020-11-26 | アルター・バイオサイエンス・コーポレーション | Il−15をベースとするil−7及びil−21への融合物 |
| JP7778571B2 (ja) * | 2019-06-05 | 2025-12-02 | アッシャー バイオセラピューティクス, インコーポレイテッド | 免疫細胞機能をモジュレートするための変異体インターロイキン-2ポリペプチドと抗原結合分子の融合体 |
| EP4175979A2 (en) * | 2020-07-02 | 2023-05-10 | Inhibrx, Inc. | Polypeptides comprising modified il-2 polypeptides and uses thereof |
| KR20230086765A (ko) * | 2020-10-13 | 2023-06-15 | 얀센 바이오테크 인코포레이티드 | 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법 |
| KR20230112632A (ko) * | 2020-10-23 | 2023-07-27 | 애셔 바이오테라퓨틱스, 인크. | 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합 |
| WO2022245500A1 (en) * | 2021-05-19 | 2022-11-24 | Asher Biotherapeutics, Inc. | Il-21 polypeptides and targeted constructs |
-
2023
- 2023-04-26 CN CN202380050634.5A patent/CN119546343A/zh active Pending
- 2023-04-26 JP JP2024563188A patent/JP2025515470A/ja active Pending
- 2023-04-26 WO PCT/US2023/019989 patent/WO2023212056A2/en not_active Ceased
- 2023-04-26 KR KR1020247039383A patent/KR20250027597A/ko active Pending
- 2023-04-26 AU AU2023259161A patent/AU2023259161A1/en active Pending
- 2023-04-26 CA CA3250301A patent/CA3250301A1/en active Pending
- 2023-04-26 US US18/859,452 patent/US20250339519A1/en active Pending
- 2023-04-26 EP EP23797206.2A patent/EP4514397A4/en active Pending
- 2023-04-27 TW TW112115849A patent/TW202400664A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3250301A1 (en) | 2023-11-02 |
| JP2025515470A (ja) | 2025-05-15 |
| EP4514397A2 (en) | 2025-03-05 |
| AU2023259161A1 (en) | 2024-11-28 |
| TW202400664A (zh) | 2024-01-01 |
| WO2023212056A2 (en) | 2023-11-02 |
| US20250339519A1 (en) | 2025-11-06 |
| WO2023212056A3 (en) | 2023-12-07 |
| EP4514397A4 (en) | 2026-05-20 |
| CN119546343A (zh) | 2025-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7778571B2 (ja) | 免疫細胞機能をモジュレートするための変異体インターロイキン-2ポリペプチドと抗原結合分子の融合体 | |
| US20230055445A1 (en) | Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof | |
| JP7148539B2 (ja) | 免疫抱合体 | |
| JP7847584B2 (ja) | 免疫細胞機能をモジュレートするためのcd8抗原結合分子を有する融合物 | |
| JP7853916B2 (ja) | 免疫複合体 | |
| US12247072B2 (en) | IL-21 polypeptides and targeted constructs | |
| KR20220079904A (ko) | 특성이 개선된 pd-1 표적 il-15/il-15r 알파 fc 융합 단백질 | |
| US20260083855A1 (en) | Immunoconjugates | |
| TW202237630A (zh) | 用於調節免疫細胞功能之突變介白素-10多肽與抗原結合分子之融合體 | |
| AU2021383879A9 (en) | Bi-functional molecules | |
| US20250339519A1 (en) | Combination of cytokine fusion proteins with cd8 antigen binding molecules | |
| US20260098090A1 (en) | Fusions with cd8 antigen binding molecules for treating chronic viral infection | |
| HK40129535A (en) | Il-21 polypeptides and targeted constructs | |
| EA051898B1 (ru) | Полипептиды il-21 и нацеленные конструкции | |
| HK40123337A (en) | Immunoconjugates | |
| EA052306B1 (ru) | Слитые белки и их применение, полинуклеотид, кодирующий их, вектор экспрессии, выделенная клетка-хозяин, способ получения слитого белка, фармацевтическая композиция, способ лечения рака, способ размножения т-клеток ex vivo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |